These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine. Karlsen SN; Spigset O; Slørdal L Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):15-24. PubMed ID: 18047478 [TBL] [Abstract][Full Text] [Related]
6. Club drug use in Germany. Soellner R Subst Use Misuse; 2005; 40(9-10):1279-93. PubMed ID: 16048817 [TBL] [Abstract][Full Text] [Related]
7. [Psychiatric disorders and consumption of ecstasy drug (MDMA): review of published case reports]. Bango J; Fadón P; Mata F; Rubio G; Santo-Domingo J Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998; 26(4):260-3. PubMed ID: 9807860 [TBL] [Abstract][Full Text] [Related]
8. [3,4-methylenedioxymethamphetamine ('ecstasy'): its long-term emotional and cognitive effects, and serotonin depletion]. Molero-Chamizo A Rev Neurol; 2005 Jul 16-31; 41(2):108-14. PubMed ID: 16028190 [TBL] [Abstract][Full Text] [Related]
9. [Effects of ecstasy on the body]. Saarijärvi S; Lopperi M Duodecim; 2003; 119(13):1211-5. PubMed ID: 12908183 [No Abstract] [Full Text] [Related]
10. Methodological problems with ecstasy and the SCL-90. Cole JC; Sumnall HR; Wagstaff GF Psychopharmacology (Berl); 2002 Jul; 162(2):215-7; discussion 218-22. PubMed ID: 12110999 [No Abstract] [Full Text] [Related]
11. Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors. Soar K; Turner JJ; Parrott AC J Psychopharmacol; 2006 May; 20(3):417-24. PubMed ID: 16574716 [TBL] [Abstract][Full Text] [Related]